Brought to you by 
Medarex, Tularik develop antibodies to treat cancer
01 Apr 2003
Executive Summary
Medarex (antibodies) will use its UltiMAb to generate fully human antibodies to three oncogenes discovered by Tularik (drugs to regulate gene expression).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medarex, Tularik develop antibodies to treat cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice